How-Sustainability-Has-Become-The-New-Innovation-Currency

A 44-minute panel discussion from the Danaher Summit 2026 on The Next Era of Bioprocessing, exploring how sustainability has become a core innovation driver in biopharma. Three panelists — Robert Barrentine (Saint-Gobain Life Sciences), Suzanne Farid (UCL), and Rob Williamson (AstraZeneca) — debate genuine industry commitment, how to embed sustainability across conflicting metrics, and what technology and collaborative mechanisms can accelerate the transition. Key themes span life cycle assessment, the mass balance approach for bio-attributed single-use materials, scope 3 supply chain engagement, and AI-enhanced carbon footprinting.

Key Takeaways

AstraZeneca has committed over $1 billion to low carbon transformation, with 1 in 9 SBT registry companies being an AZ supplier and over 80% of spend with SBT-committed suppliers; AZ has walked away from suppliers who refused to commit.
Process mass intensity and carbon footprint metrics point to fundamentally different sustainability priorities for biotherapeutics, requiring multi-criteria decision-making and industry agreement on metric weighting before sustainability can drive confident choices.
The mass balance approach enables bio-attributed feedstocks to be incorporated at the cracker step into existing validated single-use products without any physical change, is regulatorily acceptable, and has precedent in consumer products for over a decade.
The health sector creates 5% of global carbon emissions — more than aviation — making scope 3 supply chain engagement across thousands of suppliers essential to meaningful decarbonization.
PSCI has 85 member companies representing _{70% of global pharma turnover (}$1.2T aggregate); the Sustainable Markets Initiative joint supplier targets letter signed by CPOs of GSK, AstraZeneca, Roche, and others was described by suppliers as pivotal.
Circularity — reclaiming every material input — is the 'last frontier' for zero-impact biopharma beyond decarbonization; polymer recycling technology already exists in other industries and is a matter of scale and collective business case.
AI can improve LCA product carbon footprint accuracy tenfold using better proxies for missing primary data; PAS 2090 was recently published as product category rules for LCA of drug products including biologics.
Sustainability by design — embedded from the start of development and aligned with core business metrics — delivers commercial advantage through cost certainty and fossil fuel price decoupling, not just regulatory compliance.